Abivax Shares Surge 27% at the Opening of the Paris Stock Exchange
French biotech company Abivax saw its shares soar by 27.07% Monday morning, crossing the threshold of 125.80 euros, while the CAC 40 index fell by 0.55%. This movement occurs in a context of accelerated consolidation within the inflammatory bowel disease sector, where major global pharmaceutical companies are looking to secure cutting-edge oral assets.
The dynamics of the stock are part of a longer-term movement. Over seven days, Abivax has recorded a rise of 9.39%, while its quarterly performance shows a +59.04%. This rapid morning increase should be viewed in the context of the stock's dizzying annual trajectory, which has peaked at +1,844% since the beginning of 2025, a substantial difference from the broader market's twelve-month performance of +11.91%. However, exchanges remain cautious, with only 0.19% of the capital traded, reflecting a certain restraint from investors despite the displayed volatility. The monthly volatility of 28.75% and a beta of 0.15 highlight the significant gap between Abivax's movements and those of the CAC 40, positioning this stock well beyond the ordinary fluctuations of the general market.
Technical Perspective
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
From a technical standpoint, the stock is poised to test its resistance zone at 122.40 euros, which it has just surpassed. The 50-day moving average, set at 101.53 euros, remains significantly behind, confirming the recent upward trend but also the rapidity of the progression that creates a structural gap. The Relative Strength Index (RSI), positioned at 53, remains neutral and does not indicate an immediate overextension signal. The Bollinger Bands frame the movement between 90.20 euros at the bottom and 127.34 euros at the top, suggesting that the stock is approaching its upper volatility limit.
A More Nuanced View of Underlying Flows
A more nuanced reading of the underlying flows reveals certain tensions. The OBV (On-Balance Volume) shows a negative value, while the CMF (Chaikin Money Flow) is at -0.11, hinting at a discrepancy between the upward price momentum and the actual structure of liquidity flows. The MACD Histogram, recorded at -1.80, reflects a divergence between the MACD line and its signal line, pointing towards a possible moderation of the upward momentum. These indicators suggest that the morning's bullish movement, although spectacular in appearance, is accompanied by mixed technical signals regarding the sustainability of the progression.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 3T 2025
Guidance from the release
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
